Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia

Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowman, Brendan T, Rosner, Mitchell H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712664/
https://www.ncbi.nlm.nih.gov/pubmed/23874242
http://dx.doi.org/10.2147/CE.S36744
_version_ 1782277094663782400
author Bowman, Brendan T
Rosner, Mitchell H
author_facet Bowman, Brendan T
Rosner, Mitchell H
author_sort Bowman, Brendan T
collection PubMed
description Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect through blockade of its receptor in the distal tubule is an attractive therapeutic target. Lixivaptan is a newer, non-peptide, vasopressin type 2 receptor antagonist. Recent studies have demonstrated efficacy. This review summarizes the clinical pharmacology and data for this new agent.
format Online
Article
Text
id pubmed-3712664
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37126642013-07-19 Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia Bowman, Brendan T Rosner, Mitchell H Core Evid Review Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect through blockade of its receptor in the distal tubule is an attractive therapeutic target. Lixivaptan is a newer, non-peptide, vasopressin type 2 receptor antagonist. Recent studies have demonstrated efficacy. This review summarizes the clinical pharmacology and data for this new agent. Dove Medical Press 2013 2013-07-11 /pmc/articles/PMC3712664/ /pubmed/23874242 http://dx.doi.org/10.2147/CE.S36744 Text en © 2013 Bowman and Rosner, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Bowman, Brendan T
Rosner, Mitchell H
Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title_full Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title_fullStr Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title_full_unstemmed Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title_short Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
title_sort lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712664/
https://www.ncbi.nlm.nih.gov/pubmed/23874242
http://dx.doi.org/10.2147/CE.S36744
work_keys_str_mv AT bowmanbrendant lixivaptananevidencebasedreviewofitsclinicalpotentialinthetreatmentofhyponatremia
AT rosnermitchellh lixivaptananevidencebasedreviewofitsclinicalpotentialinthetreatmentofhyponatremia

Ejemplares similares